Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-450 plus Methotrexate in Rheumatoid Arthritis
NCT05279417Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of zunsemetinib in rheumatoid arthritis (RA) (3 arms), sponsored by Aclaris Therapeutics, Inc. Primary endpoint: American College of Rheumatology 20% Improvement Criteria at 12 weeks. Started Feb 2022; status: completed.
02
Drugs
zunsemetinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05279417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279417.